The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation
10.18632/oncotarget.5256 · doi-reference
Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy
10.1245/s10434-011-1638-y · doi-reference
Cell-free nucleic acids as biomarkers in cancer patients
10.1038/nrc3066 · doi-reference
Circulating tumor cells and circulating tumor DNA
10.1146/annurev-med-062310-094219 · doi-reference
Residual gammaH2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness
10.1016/j.radonc.2015.08.006 · doi-reference
Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by gammaH2AX staining
10.3109/09553000903242149 · doi-reference
Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays
10.1016/j.radonc.2006.07.026 · doi-reference
PP4 is a gamma H2AX phosphatase required for recovery from the DNA damage checkpoint
10.1038/embor.2008.162 · doi-reference
GammaH2AX as a checkpoint maintenance signal
10.4161/cc.5.13.2899 · doi-reference
A phosphatase complex that dephosphorylates gammaH2AX regulates DNA damage checkpoint recovery
10.1038/nature04384 · doi-reference
Gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair
10.1016/j.molcel.2005.10.003 · doi-reference
Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody
10.1667/0033-7587(2002)158[0486:qdoiid]2.0.co;2 · doi-reference
GammaH2AX and cancer
10.1038/nrc2523 · doi-reference
KRAS and combined KRAS/TP53 mutations in locally advanced rectal cancer are independently associated with decreased response to neoadjuvant therapy
10.1245/s10434-016-5205-4 · doi-reference
Failure of downregulation of survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival
10.1158/1078-0432.ccr-10-2592 · doi-reference
Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma
10.1200/jco.2010.32.3212 · doi-reference
The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis
10.1016/j.radonc.2004.12.021 · doi-reference
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer
10.1016/j.ijrobp.2009.03.003 · doi-reference
Performance of diffusion-weighted imaging, perfusion imaging, and texture analysis in predicting tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3T MR: initial experience
10.1007/s00261-016-0733-8 · doi-reference
External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma
10.3109/0284186x.2015.1061214 · doi-reference
Radiomics: extracting more information from medical images using advanced feature analysis
10.1016/j.ejca.2011.11.036 · doi-reference
Nomogram predicting response after chemoradiotherapy in rectal cancer using sequential PETCT imaging: a multicentric prospective study with external validation
10.1016/j.radonc.2014.11.002 · doi-reference
Magnetic resonance tumor regression grade and residual mucosal abnormality as predictors for pathological complete response in rectal cancer postneoadjuvant chemoradiotherapy
10.1097/dcr.0000000000000667 · doi-reference
Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience
10.1200/jco.2011.34.9068 · doi-reference
Pathological features of rectal cancer after preoperative radiochemotherapy
10.1007/s003840050072 · doi-reference
Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis
10.1148/radiol.13122833 · doi-reference
Clinical significance of the endoscopic finding in predicting complete tumor response to preoperative chemoradiation therapy in rectal cancer
10.1007/s00268-016-3661-4 · doi-reference
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization
10.1007/dcr.0b013e3181f42b89 · doi-reference
The role of diffusion-weighted MRI and 18 F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: A systematic review
10.1016/j.radonc.2014.11.026 · doi-reference
The MRI-Linear Accelerator Consortium: evidence-based clinical introduction of an innovation in radiation oncology connecting researchers, methodology, data collection, quality assurance, and technical development
10.3389/fonc.2016.00215 · doi-reference
Comparative treatment planning study on sequential vs. simultaneous integrated boost in head and neck cancer patients: Differences in dose distributions and potential implications for clinical practice
10.1007/s00066-015-0913-4 · doi-reference
Biological Image-Guided Radiotherapy in Rectal Cancer: Challenges and Pitfalls
10.1016/j.ijrobp.2008.11.031 · doi-reference
Analysis of motion of the rectum during preoperative intensity modulated radiation therapy for rectal cancer using cone-beam computed tomography
10.1186/s13014-014-0311-6 · doi-reference
Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis
10.1016/j.radonc.2014.08.035 · doi-reference
Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy
10.1016/j.ijrobp.2012.05.017 · doi-reference
Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum
10.3109/02656730903333958 · doi-reference
Long-term local control and survival after preoperative radiochemotherapy in combination with deep regional hyperthermia in locally advanced rectal cancer
10.3109/02656736.2015.1117661 · doi-reference
Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone
10.3109/02656736.2012.722263 · doi-reference
Stellenwert der Hyperthermie für die chirurgische Onkologie
10.1055/s-2002-36060 · doi-reference
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer
10.1016/j.ijrobp.2009.02.037 · doi-reference
